Symbols

Symbols

CGTX

CGTX

Cognition Therapeutics reaches target enrollment in Phase 2 START Study.

Cognition Therapeutics Completes Phase 2 Enrollment of Zervimesine in Early Alzheimer's Disease Study

Indian Army and Air Force Conduct Joint Exercise in Arunachal Pradesh

Thursday Nov 06, 2025

Cognition Therapeutics raises $30 mln for zervimesine development.

Cognition Therapeutics' Q3 2025 Financial Results and Clinical Program Progress: $30M Funding for Zervimesine Development and FDA Alignment on Registrational Path

Friday Oct 10, 2025

Stoke Therapeutics Stock Triggers Death Cross, Bearish Marubozu on 15-Minute Chart

Friday Sep 26, 2025

Cognition Therapeutics shares rise 3.97% premarket due to healthcare innovation trends and demand for precision healthcare solutions.

Thursday Sep 25, 2025

Cognition Therapeutics shares rise 2.22% premarket after Eisai and Biogen's LEQEMBI® approval in Australia.

Wednesday Sep 24, 2025

Cognition Therapeutics shares rise 1.49% premarket after Eisai and Biogen's LEQEMBI® approval in Australia.

Friday Sep 19, 2025

Cognition (CGTX) down more than 50% since Aug 25

Tuesday Sep 16, 2025

Cognition Therapeutics shares rise 3.25% premarket after Newron Pharmaceuticals' positive H1 2025 results and business update.

Friday Sep 12, 2025

Cognition Therapeutics shares fall 9.96% intraday due to profit-taking and confusion with Cognition AI's $400M funding.

Friday Sep 05, 2025

Cognition Therapeutics shares rise 1.93% premarket after Neuphoria Therapeutics completes target enrollment in Phase 3 trial.

Thursday Sep 04, 2025

Umecrine Cognition's golexanolone reverses neuroinflammation in Parkinson's disease model.

Karolinska Development's Portfolio Company Umecrine Cognition Presents Sustained Effect of Golexanolone in Parkinson's Disease Model

Wednesday Sep 03, 2025

Cognition Therapeutics shares fall 1.23% premarket after closing a $30 million registered direct offering.

Tuesday Sep 02, 2025

Cognition Therapeutics shares fall 2.06% after-hours following a $30 million registered direct offering.

Cognition Therapeutics Secures $30 Million in Funding to Advance Zervimesine Development

Sunday Aug 31, 2025

Argenica Therapeutics Seeks Trading Halt Amid Ongoing Clinical Trial

Friday Aug 29, 2025

Cognition Therapeutics Raises $30 Million to Fund Phase 3 Trials and Corporate Purposes